Company Announcements

CHICAGO--(BUSINESS WIRE)--Feb. 5, 2025-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will take part in the following events:

• Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual)
  • 1x1 meetings and fireside chat February 12, 2025 at 1:20 pm ET
• Leerink Global Healthcare Conference, Miami, FL
  • 1x1 meetings and fireside chat on March 10, 2025 at 8:40 am ET
• Barclays 27th Annual Global Healthcare Conference, Miami, FL
  • 1x1 meetings only on March 11, 2025

Please check with each conference sponsor to arrange 1x1 meetings.

Webcast information for each fireside chat will be available at https://xerispharma.com/investor-relations.

About Xeris

Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev^®, for the treatment of endogenous Cushing’s syndrome; Gvoke^®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis^®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as multiple early-stage programs leveraging Xeris’ technology platforms, XeriSol^® and XeriJect^®, for its partners.

Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on X, LinkedIn, or Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250205312553/en/

Investor Contact
Allison Wey
Senior Vice President, Investor Relations and Corporate Communications
awey@xerispharma.com

Source: Xeris Biopharma Holdings, Inc.